{"contentid": 488614, "importid": NaN, "name": "NICE decides not to recommend ozanimod for people with relapsing MS on the NHS", "introduction": "The UK\u00e2\u0080\u0099s National Institute for Health and Care Excellence (NICE) has made the final decision not to recommend ozanimod \u00e2\u0080\u0093 a new, oral treatment for people with relapsing multiple sclerosis (MS) \u00e2\u0080\u0093 on the National Health Service (NHS).", "content": "<p>The UK&rsquo;s National Institute for Health and Care Excellence (NICE) has made the final decision not to recommend ozanimod &ndash; a new, oral treatment for people with relapsing multiple sclerosis (MS) &ndash; on the National Health Service (NHS).</p>\n<p>In January this year, the NICE delivered a <a href=\"https://www.thepharmaletter.com/article/uk-pricing-watchdog-pushes-back-on-bristol-myers-zeposia\">negative verdict</a> on Bristol Myers Squibb&rsquo;s (NYSE: BMY) novel multiple sclerosis drug, Zeposia (ozanimod, saying that &ldquo;ozanimod's effect on the progression of disability is unclear.&rdquo; The health technology assessor said that the cost-effectiveness estimates for Zeposia were uncertain, due to limitations in the available evidence, and that it could not therefore recommend its use.</p>\n<h2><strong>MS Society disappointed</strong></h2>\n<p>Responding to the news, Fredi Cavander-Attwood, Policy manager at the MS Society, said: &ldquo;It&rsquo;s disappointing that NICE has made this final decision not to recommend ozanimod as a treatment for relapsing multiple sclerosis (MS) in England.&nbsp;Oral treatments, like ozanimod, are limited and not allowing people this option could deny them a convenient way to manage MS symptoms.</p>\n<p>&ldquo;This rejection also highlights the inequities in access to treatments around the UK, as people living with MS in Scotland were granted access to ozanimod in February. Effective MS treatments should be made available for everyone living with MS regardless of where they live in the UK.&rdquo;</p>", "date": "2021-05-13 10:26:00", "meta_title": "NICE decides not to recommend ozanimod for people with relapsing MS on", "meta_keywords": "Bristol Myers Squibb, Zeposia, Ozanimod, NICE, Not recommended, Multiple sclerosis, MS Society", "meta_description": "NICE decides not to recommend ozanimod for people with relapsing MS on the NHS", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-13 10:24:52", "updated": "2021-05-13 10:32:41", "access": NaN, "url": "https://www.thepharmaletter.com/article/nice-decides-not-to-recommend-ozanimod-for-people-with-relapsing-ms-on-the-nhs", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "nice-big-1.png", "image2id": "nice-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Musculoskeletal, Neurological", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "UK, USA", "company_tag": "Bristol-Myers Squibb", "drug_tag": "ozanimod, Zeposia", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-13 10:26:00"}